Could this breakthrough Rx fill a major treatment gap in cutaneous lupus?
Industry Buzz
The data on litifilimab are genuinely exciting for both dermatologists and rheumatologists because cutaneous lupus erythematosus (CLE) has had remarkably few therapeutic advances for decades.
—Tanya Evans, MD
Historically, drugs targeting lupus have proven difficult to develop. Therefore, there remains a need for additional large-scale Phase 3 clinical trials to provide long-term safety data and to determine which specific subpopulations of CLE patients will benefit from the use of litifilimab.
—Michael Genovese, MD, JD
If you treat patients with cutaneous lupus erythematosus (CLE), you’ll know that they’re fed up living with the rashes, scales, lesions, pigment changes, and scarring. CLE can be a life-changing diagnosis for patients.
For one thing, undeniable treatment gaps exist, with many rheumatologists unsure of how to even diagnose the disease. Further, CLE is often perceived as “less serious” than lupus nephritis, despite CLE’s immense quality-of-life burden. Patients experience more than just visible skin issues, for example; CLE can cause severe pain and even disfigurement.[]
Treatment typically involves sun protection, topical glucocorticoids, antimalarial medications, and immunosuppressive drugs—but there are no approved targeted therapies for CLE, specifically.[]
Fortunately, that could all change. According to results from the AMETHYST Phase 2/3 study, investigational litifilimab—a first-in-class, humanized IgG1 monoclonal antibody for CLE—shows real promise.[]
Why litifilimab is so unique
“Litifilimab is particularly interesting because it targets a very specific immune pathway involved in lupus inflammation,” Tanya Evans, MD, dermatologist and medical director of the Skin Cancer Program at the Melanoma Clinic at MemorialCare Saddleback Medical Center in Laguna Hills, California, told MDLinx. “It is a more targeted immunologic approach rather than the broad immunosuppression traditionally used in CLE, such as corticosteroids, antimalarials, methotrexate, or mycophenolate.”
The drug targets blood dendritic cell antigen 2, or BDCA2, a receptor found mainly on plasmacytoid dendritic cells. “These cells are considered major drivers of lupus inflammation because they produce large amounts of type I interferons and other inflammatory cytokines,” Dr. Evans said.
According to the study, patients treated with litifilimab saw improved scores on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A).
Patients also saw relatively rapid improvement, achieved clear or almost clear skin compared with placebo, and experienced meaningful reductions in disease severity. “Importantly, the study included a diverse population with moderate-to-severe disease, making the results more applicable to real-world patients," Dr. Evans added.
For this reason, the U.S. Food and Drug Administration (FDA) granted litifilimab Breakthrough Therapy Designation to expedite the drug’s development and review.[]
“The data on litifilimab are genuinely exciting for both dermatologists and rheumatologists because cutaneous lupus erythematosus (CLE) has had remarkably few therapeutic advances for decades,” Dr. Evans said. If successful in Phase 3, litifilimab could represent a shift toward precision therapy in cutaneous lupus.”
Why experts are optimistic—but cautious
Michael Genovese, MD, JD, chief medical advisor of Ascendant New York, told MDLinx that while findings are encouraging, they require further validation.
“These are early mid-phase clinical trial data. Historically, drugs targeting lupus have proven difficult to develop. Therefore, there remains a need for additional large-scale Phase 3 clinical trials to provide long-term safety data and to determine which specific subpopulations of CLE patients will benefit from the use of litifilimab,” he says.